2Xideas AG Sells 12,419 Shares of IQVIA Holdings Inc. $IQV

2Xideas AG cut its stake in IQVIA Holdings Inc. (NYSE:IQV) by 19.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 50,475 shares of the medical research company’s stock after selling 12,419 shares during the quarter. IQVIA accounts for about 2.0% of 2Xideas AG’s investment portfolio, making the stock its 12th largest holding. 2Xideas AG’s holdings in IQVIA were worth $9,587,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Eubel Brady & Suttman Asset Management Inc. bought a new position in IQVIA in the third quarter valued at about $14,278,000. Eagle Rock Investment Company LLC increased its position in shares of IQVIA by 33.6% during the 3rd quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock valued at $8,800,000 after purchasing an additional 11,657 shares during the last quarter. OPTIMAS CAPITAL Ltd bought a new position in shares of IQVIA in the 3rd quarter worth approximately $4,008,000. Amundi boosted its holdings in shares of IQVIA by 46.3% in the second quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock worth $210,722,000 after buying an additional 405,250 shares during the last quarter. Finally, EDENTREE ASSET MANAGEMENT Ltd purchased a new stake in IQVIA during the third quarter valued at approximately $7,368,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 1.1%

Shares of NYSE IQV opened at $164.78 on Friday. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The stock’s fifty day simple moving average is $201.58 and its two-hundred day simple moving average is $206.67. The stock has a market capitalization of $27.96 billion, a PE ratio of 20.96, a price-to-earnings-growth ratio of 1.57 and a beta of 1.39. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm had revenue of $4.36 billion during the quarter, compared to analysts’ expectations of $4.24 billion. During the same period in the prior year, the business posted $3.12 EPS. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on IQV shares. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the company from $174.00 to $213.00 in a research report on Monday, March 9th. JPMorgan Chase & Co. cut their price objective on IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research note on Friday, February 6th. Jefferies Financial Group decreased their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective for the company in a research note on Friday, March 6th. Finally, Truist Financial lowered their target price on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research note on Thursday, February 19th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $229.13.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.